Emerging from the Institute of Cell Culture Technology at Bielefeld University, Germany, in 2009, Xell AG (formerly TeutoCell AG) has grown to become an independent and privately financed biotech company dedicated to cutting-edge innovation and developing expertise.
With more than 20 years of hands-on experience in cell culture technology, Xell has drawn from its academic and technological knowledge to become a key partner in the design and distribution of cell culture solutions. They launched their first commercial products for CHO and hybridoma cell lines in 2010, and since then, Xell has continuously developed new tools for mammalian cell cultivation, benefiting from strong partnerships in industry and academia.
2015 saw Xell move to a new facility, and this gave them the additional capacity they needed to expand their portfolio of innovative off-the-shelf media. In 2019, a brand-new manufacturing facility was brought into operation, supporting large-scale production of liquid and dry powder formulations such as cell culture media, buffer and medical products. Today Xell has three main independent business divisions that work together closely:
Production of liquid and dry powder formulations – from cell culture media and feeds for CHO, HEK , BHK and hybridoma , to buffers and medical products
Analytics of spent media, food, feed and other sample types
Research and development – cell culture and process optimization services to enhance our customers’ knowledge and performance
Besides their ISO 9001 certification (Quality management system) obtained in 2019, they are working on their ISO 13485 certification (Medical devices — Quality management system) for 2021.